Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2016 March;82(3) > Minerva Anestesiologica 2016 March;82(3):343-58

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS   Freefree

Minerva Anestesiologica 2016 March;82(3):343-58

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

The role of genomics to identify biomarkers and signaling molecules during severe sepsis

James J. DOUGLAS, James A. RUSSELL

Centre for Heart Lung Innovation, St. Paul’s Hospital and University of British Columbia, Division of Critical Care Medicine, Vancouver, Canada


PDF


Early strategies to diagnose, manage and predict outcome of sepsis are essential to further improve morbidity and mortality of sepsis. Whereas biomarkers have become mainstay in other fields of medicine, their clinical utility in sepsis remains generally much less proven and so biomarkers are much less used clinically. The Human Genome Project embellished genomics, transcriptomics, proteomics and metabolomics and continues to expand our knowledge of the genetic, gene expression, protein translational and metabolic discoveries that could lead to clinical biomarker tests related to sepsis thereby allowing insight into the disease as never seen before. We explore the genomic approach to biomarker identification and validation by reviewing pertinent studies related to the diagnosis (diagnostic biomarkers), prediction of response to therapies (predictive biomarkers) and (prognostic biomarkers) outcomes of sepsis.

top of page